Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents

Journal of Cardiology

Volumn 59, Issue 1, 2012, Pages 22-29

  Li, Yong Jian ^a,b   Rha, Seung Woon ^a   Chen, Kang Yin ^c   Jin, Zhe ^b   Wang, Lin ^a   Ramasamy, Sureshkumar ^a   Poddar, Kanhaiya L ^a   Minami, Yoshiyasu ^a   Park, Ji Young ^d   Choi, Cheol Ung ^a   Oh, Dong Joo ^a   Jeong, Myung Ho ^e  

^a Korea University College of Medicine   (South Korea)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^d Eulji General Hospital   (South Korea)

^e Chonnam National University Medical School   (South Korea)

Author keywords

Acute non ST segment elevation myocardial infarction; Drug eluting stents; Enoxaparin; Percutaneous coronary intervention; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; REVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME;

ANTICOAGULANTS; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 84855186630     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.09.005     Document Type: Article

References (24)

1. Antman E.M., McCabe C.H., Gurfinkel E.P., Turpie A.G., Bernink P.J., Salein D., Bayes De Luna A., Fox K., Lablanche J.M., Radley D., Premmereur J., Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601.
2. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., Jones R.H., Kereiakes D., Kupersmith J., Levin T.N., Pepine C.J., Schaeffer J.W., Smith E.E., Steward D.E., Theroux P., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1893-1900.
3. Chen K.Y., Rha S.W., Li Y.J., Poddar K.L., Jin Z., Minami Y., Wang L., Kim E.J., Park C.G., Seo H.S., Oh D.J., Jeong M.H., Ahn Y.K., Hong T.J., Kim Y.J., et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009, 119:3207-3214.
4. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004, 364:583-591.
5. Li Y.J., Rha S.W., Chen K.Y., Jin Z., Minami Y., Wang L., Dang Q., Poddar K.L., Ramasamy S., Park J.Y., Oh D.J., Jeong M.H. Clinical characteristics and mid-term outcomes of acute myocardial infarction patients with prior cerebrovascular disease in an Asian population: lessons from the Korea Acute Myocardial Infarction Registry. Clin Exp Pharmacol Physiol 2010, 37:581-586.
6. Li Y.J., Rha S.W., Chen K.Y., Poddar K.L., Jin Z., Minami Y., Wang L., Dang Q., Li G.P., Ramasamy S., Park J.Y., Choi C.U., Kim J.W., Kim E.J., Park C.G., et al. Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. Am Heart J 2010, 159:684-690.
7. Kandzari D.E., Roe M.T., Ohman E.M., Milford-Beland S., Chen A.Y., Lytle B.L., Cohen D.J., Smith S.C., Harrington R.A., Gibler W.B., Peterson E.D. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005, 96:750-755.
8. Luscher T.F., Steffel J., Eberli F.R., Joner M., Nakazawa G., Tanner F.C., Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007, 115:1051-1058.
9. Nakagawa T., Hiasa Y., Hosokawa S., Minami T., Yano Y., Yoneda K., Mizobe M., Murakami N., Tobetto Y., Chen H., Miyazaki S., Mahara K., Ogura R., Miyajima H., Yuba K., et al. The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. J Cardiol 2011, 57:283-289.
10. Park K.H., Jeong M.H., Lee M.G., Ko J.S., Sim D.S., Yoon N.S., Yoon H.J., Hong Y.J., Kim K.H., Park H.W., Kim J.H., Ahn Y., Cho J.G., Park J.C., Kang J.C. What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?. J Cardiol 2011, 57:53-60.
11. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
12. Antman E.M. The search for replacements for unfractionated heparin. Circulation 2001, 103:2310-2314.
13. Ishikawa T., Nakano Y., Endoh A., Kubota T., Suzuki T., Nakata K., Miyamoto T., Murakami M., Sakamoto H., Imai K., Mochizuki S., Yoshimura M., Mutoh M. Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies. J Cardiol 2009, 54:238-244.
14. Gawaz M., Neumann F.J., Ott I., Schiessler A., Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93:229-237.
15. Montalescot G., Philippe F., Ankri A., Vicaut E., Bearez E., Poulard J.E., Carrie D., Flammang D., Dutoit A., Carayon A., Jardel C., Chevrot M., Bastard J.P., Bigonzi F., Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998, 98:294-299.
16. Hong Y.J., Jeong M.H., Choi Y.H., Ma E.H., Ko J.S., Lee M.G., Park K.H., Sim D.S., Yoon N.S., Youn H.J., Kim K.H., Park H.W., Kim J.H., Ahn Y., Cho J.G., et al. Differences in intravascular ultrasound findings in culprit lesions in infarct-related arteries between ST segment elevation myocardial infarction and non-ST segment elevation myocardial infarction. J Cardiol 2010, 56:15-22.
17. Montalescot G., Collet J.P., Choussat R., Ankri A., Thomas D. A rise of troponin and/or von Willebrand factor over the first 48h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol 2000, 72:293-294.
18. Montalescot G., Collet J.P., Lison L., Choussat R., Ankri A., Vicaut E., Perlemuter K., Philippe F., Drobinski G., Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000, 36:110-114.
19. Cohen M., Demers C., Gurfinkel E.P., Turpie A.G., Fromell G.J., Goodman S., Langer A., Califf R.M., Fox K.A., Premmereur J., Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452.
20. Eikelboom J.W., Anand S.S., Malmberg K., Weitz J.I., Ginsberg J.S., Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000, 355:1936-1942.
21. Ferguson J.J., Califf R.M., Antman E.M., Cohen M., Grines C.L., Goodman S., Kereiakes D.J., Langer A., Mahaffey K.W., Nessel C.C., Armstrong P.W., Avezum A., Aylward P., Becker R.C., Biasucci L., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
22. Murphy S.A., Gibson C.M., Morrow D.A., Van de Werf F., Menown I.B., Goodman S.G., Mahaffey K.W., Cohen M., McCabe C.H., Antman E.M., Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28:2077-2086.
23. Buller C.E., Pate G.E., Armstrong P.W., O'Neill B.J., Webb J.G., Gallo R., Welsh R.C. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 2006, 22:511-515.
24. Birkmeier K.A., Kastrati A., Byrne R.A., Holle H., Schulz S., Tiroch K., Kufner S., Massberg S., Laugwitz K.L., Schomig A., Mehilli J. Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. Catheter Cardiovasc Interv 2011, 77:494-501.